Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 33 peer-reviewed journal articles Updated
Radiology

How Does a Liver Hemangioma Differ From Other Liver Lesions?

At a Glance

Doctors distinguish a liver hemangioma from a cyst, adenoma, metastasis, or liver cancer by combining CT or MRI appearance with medical history. Typical hemangiomas show gradual contrast filling from the edges inward, while uncertain cases need specialist review.

In this answer

3 sections

01

The Crucial Role of Medical History

02

How Contrast Behavior Separates Lesions

03

Summary Comparison and Next Steps

A liver hemangioma is a benign (non-cancerous) cluster of blood vessels [1]. When it has a classic appearance on an imaging scan, doctors can usually diagnose it confidently without surgery or a biopsy [2].

However, when a new spot is found on the liver, radiologists must carefully differentiate a hemangioma from other possible lesions—such as cysts, adenomas, focal nodular hyperplasia (FNH), metastases, and primary liver cancers [3]. Because different types of liver spots require vastly different treatments, doctors look for specific visual clues on your scans combined with your personal medical history [4][5].

It is understandable to worry when looking at your radiology report, but do not interpret a single phrase (like “arterial enhancement”) in isolation. The full pattern and your health context are required to make an accurate diagnosis [6].

The Crucial Role of Medical History

Your background health provides the initial context for interpreting a scan. If you have a completely healthy liver and no history of cancer, an incidentally found liver lesion is highly likely to be benign [4]. However, certain risk factors shift how doctors interpret your scans:

  • Chronic Liver Disease: If you have cirrhosis, chronic hepatitis B or C, or metabolic liver disease, you are at a higher risk for hepatocellular carcinoma (HCC), the most common primary liver cancer [7][8]. While HCC can occur without cirrhosis, patients with these conditions have their scans evaluated with HCC specifically in mind [7][9].
  • Prior Cancer: A history of cancer elsewhere in the body (such as breast or colon cancer) raises the suspicion for a metastasis—cancer that has spread to the liver [4][10].
  • Medications & Hormones: Long-term use of oral contraceptives or hormone therapies is linked to hepatic adenomas, a different type of benign solid liver tumor [1].

How Contrast Behavior Separates Lesions

When you get a CT or MRI, you are usually given a contrast agent (dye). Radiologists take images at different time intervals (phases) to see how the dye enters the lesion (the arterial phase) and how it behaves on later delayed phases. This dynamic pattern is the main way doctors tell lesions apart.

Liver Hemangioma

On an MRI, a typical hemangioma is very bright on T2-weighted images (an MRI setting that highlights fluid and slow-moving blood) [11]. When contrast is given, it shows a classic pattern called progressive centripetal enhancement [12]. This means the contrast agent first appears as discontinuous peripheral nodules on the outer edges of the lesion, and then slowly fills into the center over time [13].

Note on Sclerosing Hemangiomas: Over time, some hemangiomas develop scar tissue. These atypical hemangiomas can lose their classic appearance, sometimes mimicking cancer by showing irregular margins or unusual enhancement patterns [14][15].

Simple Hepatic Cysts

A simple cyst is a thin-walled sac filled with fluid [5]. Unlike solid tumors, simple cysts do not take up contrast dye at all. They appear uniformly dark on T1-weighted MRI, very bright on T2-weighted MRI, and have no enhancing wall, septations (dividing walls), or solid nodules [5][16]. If a cyst has thick walls or solid parts, it is considered a “complex” cyst and requires further evaluation [17].

Hepatic Adenoma and Focal Nodular Hyperplasia (FNH)

Adenomas and FNH are benign solid tumors made of liver cells.

  • Adenomas often show early contrast uptake, though their enhancement can vary [18]. Advanced MRI can help identify different molecular subtypes of adenomas, which is important because certain subtypes (as well as larger sizes and male sex) carry a risk of bleeding or malignant transformation [19][20].
  • FNH usually has a central scar and strongly takes up specialized hepatobiliary MRI contrast agents [21][22]. Confidently diagnosed FNH rarely requires treatment.

Hepatocellular Carcinoma (HCC)

HCC classically shows rapid, bright enhancement when the dye first enters, followed by relative washout on later phases [23][24]. “Washout” does not mean the contrast literally leaves the tumor faster than surrounding tissue; rather, the tumor appears relatively darker compared to the background liver tissue on delayed images [23].

Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma is a cancer of the bile ducts within the liver. It often displays irregular, rim-like enhancement early on, followed by delayed enhancement in the center [25]. It can also cause the surface of the liver to pucker (capsular retraction) or cause nearby bile ducts to dilate [26]. (Note: Capsular retraction can occasionally occur in benign sclerosing hemangiomas as well).

Liver Metastasis

Metastases can vary widely in appearance depending on the original cancer [10]. Solitary metastases do occur, but they often appear as multiple lesions [4]. Some metastases look very similar to atypical or scarred hemangiomas [27].

Summary Comparison and Next Steps

Lesion Type Typical Imaging Clues Common Management Step
Typical Hemangioma Bright on T2 MRI; progressive outside-in enhancement. Usually no treatment or follow-up needed if asymptomatic.
Simple Cyst Fluid-filled; no contrast enhancement. Usually no treatment or follow-up needed.
Hepatic Adenoma Enhances early; variable appearance on MRI. Monitor size; may stop hormones or consider surgery.
Focal Nodular Hyperplasia (FNH) Central scar; takes up hepatobiliary contrast. Usually no treatment needed once confirmed.
Hepatocellular Carcinoma (HCC) Early enhancement followed by relative “washout”; often in cirrhosis. Specialized oncology care.
Cholangiocarcinoma Rim enhancement; delayed central enhancement. Specialized oncology care.
Metastasis Varies by primary cancer; often multiple. Specialized oncology care.

Getting an exact diagnosis dictates the next steps for your health. If you have a confidently characterized simple cyst or typical hemangioma and no symptoms, these usually require no treatment, surgery, or follow-up imaging [2][28]. Adenomas may require stopping hormone medications or surgical removal [29][30]. However, do not stop prescribed hormones without discussing it with your doctor first.

What If the Diagnosis Is Uncertain?

If imaging cannot definitively characterize your lesion, you may be referred to a multidisciplinary tumor board [31]. This is simply a group of specialists (such as radiologists, hepatologists, surgeons, and oncologists) who review complex cases together; being referred there does not automatically mean you have cancer [31].

A note on biopsies: Suspected hemangiomas are generally not biopsied routinely because of the risk of bleeding [32]. Image-guided biopsy is usually a last resort, considered only after expert review when the diagnosis remains uncertain and the results would significantly change your treatment plan [33].

Common questions in this guide

What does a typical liver hemangioma look like on CT or MRI?
On MRI, a typical liver hemangioma is very bright on T2-weighted images. After contrast, it usually shows discontinuous nodules around the edge that gradually fill toward the center, a pattern called progressive centripetal enhancement. When this pattern is clear, doctors can often diagnose it without surgery or biopsy.
How can doctors tell a liver hemangioma from a simple cyst?
A simple liver cyst is a fluid-filled sac that stays dark on T1 MRI, bright on T2 MRI, and does not take up contrast. A hemangioma is made of blood vessels and typically shows gradual contrast filling from the outside toward the center. Thick cyst walls, internal divisions, or solid nodules make a cyst complex and may require more evaluation.
How is a liver hemangioma different from an adenoma or FNH?
A hepatic adenoma is a benign solid tumor of liver cells that often enhances early and may be linked to long-term hormone use; its size and subtype can affect bleeding or cancer risk. Focal nodular hyperplasia (FNH) often has a central scar and takes up specialized liver MRI contrast, and it usually needs no treatment once confirmed. A hemangioma instead typically has bright T2 signal and progressive outside-in contrast filling.
Could a liver hemangioma be mistaken for liver cancer?
Yes. A sclerosing hemangioma can develop scar tissue and lose its typical appearance, sometimes resembling cancer on imaging. Doctors interpret the complete CT or MRI pattern together with your liver health and cancer history rather than relying on one phrase such as washout or delayed enhancement.
Which health conditions or medicines affect how a liver lesion is interpreted?
Cirrhosis, chronic hepatitis B or C, and metabolic liver disease increase concern for hepatocellular carcinoma. A previous cancer elsewhere raises concern for metastasis, while long-term oral contraceptive or hormone therapy use can point toward a hepatic adenoma. Tell your clinician about these conditions and medicines before the scan is interpreted.
Does a suspected liver hemangioma need a biopsy?
Usually not when imaging shows the classic hemangioma pattern, because biopsy can cause bleeding. If the lesion remains unclear after expert imaging review, a biopsy may be considered only when its result would change treatment. Ask why it is needed and what alternatives and bleeding risks exist.
What happens when CT or MRI cannot identify a liver lesion with certainty?
Your case may be reviewed by a multidisciplinary liver tumor board, which can include radiologists, liver specialists, surgeons, and oncologists. This referral does not by itself mean you have cancer. The team may recommend expert review, additional imaging, monitoring, or another step based on the full clinical picture.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you explain the specific enhancement pattern my lesion showed on the MRI or CT scan?
  2. 2.Does my medical history, such as any underlying liver conditions or prior cancers, change how you interpret this scan?
  3. 3.Are there any atypical features, like scarring (sclerosis) or complex cysts, that make this lesion harder to identify?
  4. 4.If this scan is indeterminate, should my case be reviewed by a specialized multidisciplinary liver tumor board?
  5. 5.If a biopsy is being proposed, why is it needed, what are the alternatives, and what are the bleeding risks?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are Liver Hemangiomas Hereditary? Should Family Be Screened?Are Multiple Liver Hemangiomas Dangerous or Treatable?Does a Liver Hemangioma Affect Liver Function or Lifespan?Does a Typical Liver Hemangioma Need Follow-Up Scans?Does Cirrhosis or Cancer Change Liver Hemangioma Diagnosis?Does Rapid Growth of a Liver Hemangioma Mean It Is Cancer?How Common Are Adult Liver Hemangiomas, and Who Gets Them?How Do Doctors Know a Liver Hemangioma Causes Pain?How Fast Do Liver Hemangiomas Grow, Shrink, or Stay Stable?Is Contrast Imaging Safe for Liver Hemangioma Patients?How Much Liver Hemangioma Growth Is Significant on Scans?Do Liver Hemangiomas Need Blood Tests or Tumor Markers?What Causes a Liver Hemangioma? Is It Present at Birth?What Does Peripheral Nodular Enhancement Mean in Hemangioma?How Often Is a Large or Atypical Liver Hemangioma Scanned?What If a Liver Hemangioma Is Indeterminate or Atypical?What Is the Best Scan to Diagnose a Liver Hemangioma?What Size Is Considered a 'Giant' Liver Hemangioma?Why Is Liver Biopsy Avoided for Hemangioma, and When Needed?

References

References (33)
  1. 1

    Benign Liver Tumors.

    Oldhafer KJ, Habbel V, Horling K, et al.

    Visceral medicine 2020; (36(4)):292-303 doi:10.1159/000509145.

    PMID: 33005655
  2. 2

    Non-invasive diagnosis and follow-up of benign liver tumours.

    Nault JC, Blanc JF, Moga L, et al.

    Clinics and research in hepatology and gastroenterology 2022; (46(1)):101765 doi:10.1016/j.clinre.2021.101765.

    PMID: 34333196
  3. 3

    Imaging features and management of focal liver lesions.

    Kahraman G, Haberal KM, Dilek ON

    World journal of radiology 2024; (16(6)):139-167 doi:10.4329/wjr.v16.i6.139.

    PMID: 38983841
  4. 4

    WFUMB Review Paper. Incidental Findings in Otherwise Healthy Subjects, How to Manage: Liver.

    Șirli R, Popescu A, Jenssen C, et al.

    Cancers 2024; (16(16)) doi:10.3390/cancers16162908.

    PMID: 39199678
  5. 5

    Management of Simple Hepatic Cyst.

    Shimizu T, Yoshioka M, Kaneya Y, et al.

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2022; (89(1)):2-8 doi:10.1272/jnms.JNMS.2022_89-115.

    PMID: 34526451
  6. 6

    Focal Benign Liver Lesions and Their Diagnostic Pitfalls.

    Reizine E, Mulé S, Luciani A

    Radiologic clinics of North America 2022; (60(5)):755-773 doi:10.1016/j.rcl.2022.05.005.

    PMID: 35989043
  7. 7

    Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips.

    Kim JH, Yoon JH, Joo I, Lee JM

    Journal of magnetic resonance imaging : JMRI 2021; (53(3)):655-675 doi:10.1002/jmri.27213.

    PMID: 32700807
  8. 8

    Geographic diversity of human liver cancers mirrors global social inequalities.

    Cano L, Foucher F, Musso O

    Frontiers in oncology 2025; (15()):1565692 doi:10.3389/fonc.2025.1565692.

    PMID: 40452835
  9. 9

    Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

    Nadarevic T, Giljaca V, Colli A, et al.

    The Cochrane database of systematic reviews 2021; (10()):CD013362 doi:10.1002/14651858.CD013362.pub2.

    PMID: 34611889
  10. 10

    Hepatobiliary contrast agents for Liver Magnetic Resonance Imaging.

    Perez-Girbes A, Lee JM, Martí-Bonmatí L

    Radiologia 2024; (66 Suppl 2()):S75-S88 doi:10.1016/j.rxeng.2024.05.002.

    PMID: 39603743
  11. 11

    Mildly Increased 68 Ga-Pentixafor Uptake in Hepatic Hemangioma.

    Yang L, Huang M, Tian R, Li Q

    Clinical nuclear medicine 2024; (49(12)):e721-e722 doi:10.1097/RLU.0000000000005484.

    PMID: 39385358
  12. 12

    Diagnosis and Management of Benign Liver Tumors.

    Ha Y

    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2025; (85(3)):314-318 doi:10.4166/kjg.2025.046.

    PMID: 40709423
  13. 13

    One stop shop approach for the diagnosis of liver hemangioma.

    Sandulescu LD, Urhut CM, Sandulescu SM, et al.

    World journal of hepatology 2021; (13(12)):1892-1908 doi:10.4254/wjh.v13.i12.1892.

    PMID: 35069996
  14. 14

    Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor.

    Kim YY, Kang TW, Cha DI, et al.

    European journal of radiology 2021; (135()):109474 doi:10.1016/j.ejrad.2020.109474.

    PMID: 33352374
  15. 15

    Hepatic Sclerosed Hemangioma: a case report and review of the literature.

    Miyamoto S, Oshita A, Daimaru Y, et al.

    BMC surgery 2015; (15()):45 doi:10.1186/s12893-015-0029-x.

    PMID: 25927893
  16. 16

    An updated review of cystic hepatic lesions.

    Rawla P, Sunkara T, Muralidharan P, Raj JP

    Clinical and experimental hepatology 2019; (5(1)):22-29 doi:10.5114/ceh.2019.83153.

    PMID: 30915403
  17. 17

    Multi-Center Follow-up Study to Develop a Classification System Which Differentiates Mucinous Cystic Neoplasm of the Liver and Benign Hepatic Cyst Using Machine Learning.

    Hardie AD, Chamberlin JH, Boyum JH, et al.

    Academic radiology 2022; (29(8)):1149-1156 doi:10.1016/j.acra.2021.08.025.

    PMID: 34598868
  18. 18

    Fat in mass in primary liver lesions: are usual MRI diagnostic criteria of both malignant and benign liver lesions still applicable?

    Reizine E, Meurgey A, Amaddeo G, et al.

    Abdominal radiology (New York) 2022; (47(7)):2347-2355 doi:10.1007/s00261-022-03561-x.

    PMID: 35672475
  19. 19

    A Shifting Paradigm in Diagnosis and Management of Hepatic Adenoma.

    Krause K, Tanabe KK

    Annals of surgical oncology 2020; (27(9)):3330-3338 doi:10.1245/s10434-020-08580-w.

    PMID: 32542565
  20. 20

    A systematic review on the complications and management of hepatic adenomas: a call for a new approach.

    Rodrigues BT, Mei SLCY, Fox A, et al.

    European journal of gastroenterology & hepatology 2020; (32(8)):923-930 doi:10.1097/MEG.0000000000001766.

    PMID: 32433418
  21. 21

    Imaging Findings in Cirrhotic Liver: Pearls and Pitfalls for Diagnosis of Focal Benign and Malignant Lesions.

    Liu X, Tan SBM, Awiwi MO, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2023; (43(9)):e230043 doi:10.1148/rg.230043.

    PMID: 37651277
  22. 22

    Dual-Contrast Agent Liver MRI for Liver Lesion Characterization.

    Shetty AS, Ludwig DR, Fraum TJ, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2026; (46(1)):e250113 doi:10.1148/rg.250113.

    PMID: 41411165
  23. 23

    [Liver Cancer].

    Yamashita T, Kaneko S

    Rinsho byori. The Japanese journal of clinical pathology 2016; (64(7)):787-796.

    PMID: 30695467
  24. 24

    Gadoxetic acid in hepatocellular carcinoma and liver metastases: pearls and pitfalls.

    Kwok HM, Chau CM, Lee HCH, et al.

    Clinical radiology 2023; (78(10)):715-723 doi:10.1016/j.crad.2023.06.005.

    PMID: 37453807
  25. 25

    Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI.

    Kovač JD, Janković A, Đikić-Rom A, et al.

    Current oncology (Toronto, Ont.) 2022; (29(2)):698-723 doi:10.3390/curroncol29020061.

    PMID: 35200560
  26. 26

    Intrahepatic mass-forming cholangiocarcinoma and solitary hypovascular liver metastases: is the differential diagnosis using diffusion-weighted MRI possible?

    Kovač JD, Galun D, Đurić-Stefanović A, et al.

    Acta radiologica (Stockholm, Sweden : 1987) 2017; (58(12)):1417-1426 doi:10.1177/0284185117695666.

    PMID: 28350257
  27. 27

    Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: Report of a case.

    Wakasugi M, Ueshima S, Tei M, et al.

    International journal of surgery case reports 2015; (8C()):137-40.

    PMID: 25679307
  28. 28

    Cystic liver lesions: a pictorial review.

    Chenin M, Paisant A, Lebigot J, et al.

    Insights into imaging 2022; (13(1)):116 doi:10.1186/s13244-022-01242-3.

    PMID: 35838923
  29. 29

    Retrospective study on timing of resection of hepatocellular adenoma.

    Klompenhouwer AJ, Bröker MEE, Thomeer MGJ, et al.

    The British journal of surgery 2017; (104(12)):1695-1703 doi:10.1002/bjs.10594.

    PMID: 28857134
  30. 30

    β-Catenin-activated inflammatory hepatocellular adenoma with pigmentation and atypical features: a case report.

    Wakasa Y, Toyoki Y, Kusumi T, et al.

    Clinical journal of gastroenterology 2023; (16(2)):237-243 doi:10.1007/s12328-023-01757-2.

    PMID: 36640247
  31. 31

    Diagnosis and Follow-up of Incidental Liver Lesions in Children.

    Karmazyn B, Rao GS, Johnstone LS, et al.

    Journal of pediatric gastroenterology and nutrition 2022; (74(3)):320-327 doi:10.1097/MPG.0000000000003377.

    PMID: 34984985
  32. 32

    Utility of contrast-enhanced ultrasonography with perflubutane in evaluating indications for diagnostic percutaneous tumor biopsy in a case of hepatic sclerosed hemangioma.

    Ando Y, Ishigami M, Ishizu Y, et al.

    Clinical journal of gastroenterology 2018; (11(6)):514-520 doi:10.1007/s12328-018-0880-2.

    PMID: 29931440
  33. 33

    Approach to the Solitary Liver Lesion: Imaging and When to Biopsy.

    Pang EH, Harris AC, Chang SD

    Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 2016; (67(2)):130-48.

    PMID: 26702758

This page is for informational purposes only and does not constitute medical advice. A radiologist or liver specialist should interpret your imaging and explain whether biopsy or follow-up is appropriate for you.

Get notified when new evidence is published on liver hemangioma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.